Oral Therapies in Psoriasis Management: A Debate on Deucravacitinib vs Apremilast - Episode 8
Looking to the Future of Oral Therapies in Psoriasis Care
Panelists discuss how the treatment landscape for psoriasis continues to evolve, with oral agents expected to play an expanding role alongside biologics. Ongoing innovation in TYK2 inhibition and PDE4 modulation may yield even more effective and tolerable options, reshaping patient expectations for convenience and control. Panelists discuss how integration of real-world data and head-to-head comparisons will clarify positioning of oral therapies across disease severities. Future directions include exploring combination strategies and earlier oral intervention to delay or reduce biologic use. Panelists discuss how continued advancement in oral therapy represents a broader shift toward personalized, accessible psoriasis care that empowers patients and supports sustained disease control.
Panelists discuss how the treatment landscape for psoriasis continues to evolve, with oral agents expected to play an expanding role alongside biologics. Ongoing innovation in TYK2 inhibition and PDE4 modulation may yield even more effective and tolerable options, reshaping patient expectations for convenience and control.
Panelists discuss how integration of real-world data and head-to-head comparisons will clarify positioning of oral therapies across disease severities. Future directions include exploring combination strategies and earlier oral intervention to delay or reduce biologic use.
Panelists discuss how continued advancement in oral therapy represents a broader shift toward personalized, accessible psoriasis care that empowers patients and supports sustained disease control.
